E14-01: Image guided radiotherapy (IGRT): physicist's perspective  by Keall, Paul J.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS264
complete pathologic response rate of 9.5% , and 7-year disease-free and 
overall-survival rates of 77% and 79% respectively[11, 12]. 
In general, it is recommended that patients with locally-advanced 
thymic tumors that initially appear inoperable undergo induction che-
motherapy with reassessment for potential surgical resection following 
chemotherapy. A prospective study of a multimodality management 
strategy in thymic tumors found that, compared to historical controls, 
chemotherapy and radiation following surgery appeared to improve 
outcomes for medium risk and high risk thymic tumors[13]. Medium 
risk thymic tumors were deﬁned as stage I and II cortical thymomas/
thymic carcinomas or stage II mixed thymoma, and high risk tumors 
were deﬁned as stage III and IV cortical thymomas/thymics carcinoma 
and stage III mixed thymomas. 
Patients with locally advanced thymic tumors who remain unresectable 
following induction chemotherapy may still be approached with cura-
tive intent via aggressive thoracic radiation. In a phase II Intergroup 
study evaluating 54Gy of radiation following two to four cycles of 
induction PAC (with additional chemotherapy administration following 
radiation), the 5-year failure-free survival was 54% while the median 
time to treatment failure was 93 months[14]. 
Thymic carcinomas appear histologically malignant and follow a more 
aggressive clinical course than thymomas. They display a greater ten-
dency for hematogenous metastasis and carry a worse prognosis. Given 
the rarity of this histologic subtype, prospective phase II studies of 
chemotherapy in only thymic carcinomas are rare. Nonetheless, it does 
appear that while thymic carcinomas are less responsive to chemothera-
py than thymomas, responses nonethless can and do occur[1, 15, 16].
While thymomas and thymic carcinomas can respond to chemotherapy, 
it is critical to remember that chemotherapy is not a cure for widely 
metastatic disease. Thymomas in particular can exhibit an indolent 
course with patients remaining asymptomatic for extended periods 
of time. Therefore, the judicious use of watchful waiting interspersed 
with intermittent, appropriately-timed chemotherapy can optimize the 
survival, symptom palliation, and quality of life for these patients.
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There is convincing clinical evidence that image guided radiotherapy 
can substantially increase the therapeutic ratio for a number of dif-
ferent cancer sites. Image guided radiotherapy is a fast-growing and 
technically complex ﬁeld, with many available commercial options to 
improve beam-target alignment. There is also substantial research and 
development into improved image guided technologies. The clinical 
rationale, current available solutions and future prospects of image 
guided therapy will be discussed. 
Educational objectives:
(1) Understand the clinical rationale for improved target accuracy in 
radiotherapy
(2) Describe several available technologies that perform image-guided 
radiotherapy
(3) Understand future developments in image guided radiotherapy
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Introduction: Stereotactic body radiotherapy (SBRT) is a new tech-
nique, introduced in the late 1990s. SBRT is a method of using single 
10-20Gy of high dose and hypofractionated radiotherapy using three-
dimensional conformal technique. Several respiratory regulation meth-
ods have been developed. Recently, many papers have been published 
on its clinical results, in early-stage lung cancer, liver cancer and other 
extracranical tumors. The purpose of this presentation is to evaluate 
